{"id":"standard-dapt-of-ticagrelor-plus-aspirin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding (major and minor)"},{"rate":"5-10","effect":"Dyspnea"},{"rate":"3-5","effect":"Bradycardia"},{"rate":"1-3","effect":"Gastrointestinal bleeding"},{"rate":"<1","effect":"Intracranial hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL398435","moleculeType":"Small molecule","molecularWeight":"522.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor is a P2Y12 receptor antagonist that reversibly blocks ADP-induced platelet activation, while aspirin irreversibly inhibits cyclooxygenase (COX) to reduce thromboxane A2 production. Together, this dual antiplatelet therapy (DAPT) provides synergistic inhibition of platelet function, reducing thrombotic events in acute coronary syndromes and after percutaneous coronary intervention.","oneSentence":"Ticagrelor and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:08.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)"},{"name":"Secondary prevention of thrombotic cardiovascular events post-ACS"}]},"trialDetails":[{"nctId":"NCT07374718","phase":"NA","title":"Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-03-01","conditions":"Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)","enrollment":468},{"nctId":"NCT06535568","phase":"NA","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","status":"RECRUITING","sponsor":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","startDate":"2026-01-10","conditions":"Coronary Disease, Heart Diseases, Cardiovascular Diseases","enrollment":576},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT07164859","phase":"PHASE3","title":"Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI","status":"NOT_YET_RECRUITING","sponsor":"Vincent ROULE","startDate":"2025-10","conditions":"Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI), Antiplatelet Therapy","enrollment":1700},{"nctId":"NCT05732701","phase":"NA","title":"Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-06-27","conditions":"Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease","enrollment":2788},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":"Chronic Coronary Syndrome","enrollment":1000},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT06943586","phase":"NA","title":"Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-09","conditions":"Stroke, Transient Ischemic Attack (TIA)","enrollment":200},{"nctId":"NCT06742567","phase":"PHASE3","title":"Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction","status":"RECRUITING","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2024-12-02","conditions":"Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus, Prophylaxis","enrollment":472},{"nctId":"NCT06683300","phase":"","title":"Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-11","conditions":"Vertebral Artery Stenosis","enrollment":520},{"nctId":"NCT04937699","phase":"PHASE4","title":"Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-28","conditions":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","enrollment":2690},{"nctId":"NCT04240834","phase":"PHASE4","title":"Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2021-02-01","conditions":"Acute Coronary Syndrome, Interventional Cardiology","enrollment":1220},{"nctId":"NCT04307511","phase":"PHASE4","title":"A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients","status":"RECRUITING","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-04-20","conditions":"Acute Coronary Syndrome Patients With Diabetes After PCI","enrollment":40},{"nctId":"NCT06013020","phase":"PHASE4","title":"Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":374},{"nctId":"NCT05262803","phase":"PHASE4","title":"Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction","status":"RECRUITING","sponsor":"Rikke Sorensen","startDate":"2022-06-17","conditions":"Myocardial Infarction","enrollment":2808},{"nctId":"NCT05773989","phase":"PHASE4","title":"Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy","status":"UNKNOWN","sponsor":"St. Antonius Hospital","startDate":"2024-01-23","conditions":"Coronary Artery Disease, Platelet Reactivity","enrollment":88},{"nctId":"NCT04307485","phase":"PHASE4","title":"A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients","status":"UNKNOWN","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-03-10","conditions":"Senior Acute Coronary Syndrome Patients After PCI","enrollment":40},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT03797651","phase":"NA","title":"Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-04-24","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":2850},{"nctId":"NCT02018055","phase":"PHASE4","title":"TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2014-02-14","conditions":"Acute Myocardial Infarction","enrollment":2590},{"nctId":"NCT04501900","phase":"PHASE4","title":"The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-10","conditions":"Cardiovascular Diseases","enrollment":2106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DAPT"],"phase":"marketed","status":"active","brandName":"Standard-DAPT of Ticagrelor plus aspirin","genericName":"Standard-DAPT of Ticagrelor plus aspirin","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of thrombotic cardiovascular events post-ACS.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}